Literature DB >> 29705930

United States National Trends in Mortality, Length of Stay (LOS) and Associated Costs of Cognitive Impairment in HIV Population from 2005 to 2014.

Smit Patel1, Neil U Parikh2, Ravikumar Aalinkeel3, Jessica L Reynolds3, Rashmi Dmello3, Stanley A Schwartz3, Supriya D Mahajan4.   

Abstract

We evaluated national trends of in-hospital discharge rates, mortality outcomes, health care costs, length of stay in HIV patients with cognitive disorders. Neurological involvement in HIV is commonly associated with cognitive impairment termed as HIV-associated neurocognitive disorder (HAND) which includes a spectrum of neurocognitive dysfunction associated with HIV infection. Although severe and progressive neurocognitive impairment has become rare in HIV patients in the era of potent antiretroviral therapy, a majority of HIV patients have mild to moderate degree of neurocognitive impairment. Study population for this analysis was derived from the Nationwide Inpatient Sample from 2005 to 2014. Patients with ICD-9 code of HIV (042) with discharge diagnosis (Dx) listed top 1 through 5 were included in the analysis. Within this population, we identified patients with cognitive impairment using ICD-9 codes of 294 (persistent mental disorders; organic psychotic brain syndromes (chronic), 323.9 (encephalitis, myelitis, and encephalomyelitis), 331.83 (mild cognitive impairment) with Dx listed from 1 to 25. Patient variables obtained included: age, race, gender, length of stay, in-hospital mortality and insurance status. Hospital level variables included teaching status, location and region of country. SAS 9.4 software was used for data analysis. Comparisons of variables between hospitalized HIV patients with and without HAND showed significant increase in cost per hospital admissions, longer hospital stay and higher risk of mortality in patients with HAND.

Entities:  

Keywords:  Co-morbidity; HIV associated neurological disorders (HAND); ICD-9 codes; Morbidity; Mortality; Nationwide Inpatient Sample database (NIS)

Mesh:

Year:  2018        PMID: 29705930     DOI: 10.1007/s10461-018-2128-z

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  7 in total

1.  Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm.

Authors:  Lucette A Cysique; Bruce J Brew
Journal:  J Neurovirol       Date:  2019-01-11       Impact factor: 2.643

2.  Utility of the International HIV Dementia Scale for HIV-Associated Neurocognitive Disorder.

Authors:  Maria Molinaro; Ned Sacktor; Gertrude Nakigozi; Aggrey Anok; James Batte; Alice Kisakye; Richard Myanja; Noeline Nakasujja; Kevin R Robertson; Ronald H Gray; Maria J Wawer; Deanna Saylor
Journal:  J Acquir Immune Defic Syndr       Date:  2020-03-01       Impact factor: 3.771

3.  HIV Nef and Antiretroviral Therapy Have an Inhibitory Effect on Autophagy in Human Astrocytes that May Contribute to HIV-Associated Neurocognitive Disorders.

Authors:  Laura Cheney; Hillary Guzik; Frank P Macaluso; Fernando Macian; Ana Maria Cuervo; Joan W Berman
Journal:  Cells       Date:  2020-06-09       Impact factor: 6.600

4.  Neurocognitive status and risk of mortality among people living with human immunodeficiency virus: an 18-year retrospective cohort study.

Authors:  Zaeema Naveed; Howard S Fox; Christopher S Wichman; Morshed Alam; Pamela May; Christine M Arcari; Jane Meza; Steven Totusek; Lorena Baccaglini
Journal:  Sci Rep       Date:  2021-02-12       Impact factor: 4.379

5.  Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus.

Authors:  Bernadette Jakeman; Alexandra U Scherrer; Katharine E A Darling; Jose Damas; Melanie Bieler-Aeschlimann; Barbara Hasse; Ladina Schlosser; Anna Hachfeld; Klemens Gutbrod; Philip E Tarr; Alexandra Calmy; Frederic Assal; Ursula Kunze; Marcel Stoeckle; Patrick Schmid; Gianina Toller; Stefania Rossi; Caroline di Benedetto; Renaud du Pasquier; Matthias Cavassini; Catia Marzolini
Journal:  Open Forum Infect Dis       Date:  2022-09-02       Impact factor: 4.423

6.  Methamphetamine induces transcriptional changes in cultured HIV-infected mature monocytes that may contribute to HIV neuropathogenesis.

Authors:  Vanessa Chilunda; Jessica Weiselberg; Samuel Martinez-Meza; Lwidiko E Mhamilawa; Laura Cheney; Joan W Berman
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

7.  Characterization of HIV-Associated Neurocognitive Impairment in Middle-Aged and Older Persons With HIV in Lima, Peru.

Authors:  Monica M Diaz; Marcela Gil Zacarías; Patricia Sotolongo; María F Sanes; Donald J Franklin; María J Marquine; Mariana Cherner; Cesar Cárcamo; Ronald J Ellis; Serggio Lanata; Patricia J García
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.